Lisinopril an ace inhibitor
Searched over 200M research papers
Summary
10 papers analyzed
These studies suggest lisinopril is an ACE inhibitor.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Lisinopril as an ACE Inhibitor: Efficacy and Applications
Introduction to Lisinopril and ACE Inhibition
Lisinopril is a widely used angiotensin-converting enzyme (ACE) inhibitor, primarily prescribed for managing hypertension, heart failure, and acute myocardial infarction. ACE inhibitors function by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby reducing blood pressure and alleviating strain on the heart .
Efficacy in Heart Failure Management
High vs. Low Doses in Heart Failure
The ATLAS study compared the effects of low and high doses of lisinopril in patients with chronic heart failure. The study found that high doses of lisinopril significantly reduced the risk of death or hospitalization and decreased hospitalizations for heart failure compared to low doses. However, high doses were associated with increased dizziness and renal insufficiency. This suggests that while higher doses may offer more significant benefits, they also come with increased risks.
Comparative Studies with Other ACE Inhibitors
A study comparing once-daily lisinopril with twice-daily captopril in patients with mild-to-moderate heart failure found that both medications significantly increased exercise duration and were well tolerated. There were no significant differences in the impact on ventricular ectopic counts or other side effects between the two drugs. This indicates that lisinopril is as effective as other ACE inhibitors in managing heart failure.
Impact on Diabetic Patients with Acute Myocardial Infarction
Lisinopril has shown significant benefits in diabetic patients with acute myocardial infarction (MI). The GISSI-3 study demonstrated that early treatment with lisinopril reduced 6-week mortality in diabetic patients, with the benefits persisting at 6 months. This supports the early and widespread use of ACE inhibitors in diabetic patients with acute MI to improve survival rates.
Genetic Factors in Renal Disease Progression
The EURODIAB Controlled Trial of Lisinopril in IDDM explored the influence of ACE gene polymorphism on renal disease progression in insulin-dependent diabetes mellitus (IDDM) patients. The study found that patients with the II genotype had a faster rate of albumin excretion rate (AER) progression on placebo but responded better to lisinopril treatment compared to other genotypes. This suggests that genetic factors may influence the efficacy of lisinopril in preventing renal disease progression.
Interaction with ACE2 and Implications for COVID-19
Recent research has indicated that lisinopril increases tissue levels of ACE2, the receptor for SARS-CoV-2, in various tissues including the lung, kidney, and small intestine. This raises questions about the potential implications of ACE inhibitors in the context of COVID-19, as increased ACE2 levels could theoretically affect viral entry and disease progression.
Pharmacokinetics and Domain Selectivity
Lisinopril-tryptophan (LisW-S), a novel derivative of lisinopril, has been developed to selectively inhibit the C-domain of ACE. This selectivity could potentially reduce side effects associated with non-selective ACE inhibition. Pharmacokinetic studies in rats have shown that LisW-S has a modest oral bioavailability and a terminal elimination half-life of around 3.1 hours, providing a basis for further clinical evaluation .
Conclusion
Lisinopril is a potent ACE inhibitor with proven efficacy in managing heart failure, reducing mortality in diabetic patients with acute MI, and potentially influencing renal disease progression based on genetic factors. While it shows promise in various therapeutic areas, its interaction with ACE2 and implications for COVID-19 warrant further investigation. The development of domain-selective inhibitors like LisW-S may offer new avenues for treatment with potentially fewer side effects.
Sources and full results
Most relevant research papers on this topic
